Clinical trial / 1986
In long-term follow-up of the Coronary Drug Project, prior niacin treatment reduced all-cause mortality by 11% compared with placebo.
The Coronary Drug Project evaluated the long-term efficacy and safety of five lipid-influencing drugs versus placebo in 8,341 men with previous myocardial infarction. At trial termination, niacin modestly decreased nonfatal recurrent myocardial infarction but not total mortality. After a mean follow-up of 15 years (nearly 9 years post-trial), all-cause mortality in the niacin group was 11% lower than in the placebo group (52.0% vs. 58.2%; p = 0.0004), while mortality in other drug groups was similar to placebo.
- Study type
- Randomized controlled trial follow-up
- Who was studied
- 8,341 men aged 30 to 64 years with previous myocardial infarction
- What was measured
- All-cause mortality and recurrent nonfatal myocardial infarction
THE PAPER
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin.
Canner PL, Berge KG, Wenger NK, Stamler J, Friedman L, Prineas RJ, Friedewald W. J Am Coll Cardiol, 1986.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.